varying immunophenotypic, cytogenetic and possibly clinical features. [5] [6] [7] [8] [9] [10] [11] [12] [13] Currently, the WHO classification defines two types of FL grade 3, one being composed of centroblasts and centrocytes (FL3A), the other harbouring centroblasts exclusively (FL3B). 1 While FL3A more closely resembles FL1 and 2, FL3B was found to display more variable immunophenotypic and genetic features. 10;11 We and others 5;6;10;11 have reported that FL3B is often t(14;18)/BCL2 rearrangement negative and is associated with a DLBCL component in the large majority of cases (the former centroblastic lymphoma, follicular and diffuse, of the Kiel classification 14 ). In the third edition of the WHO classification, FL grade 3 was defined as a tumour with an at least partly follicular growth pattern harbouring more than 150 centroblasts per 10 high power fields. This definition was adopted in most reports describing the cytogenetic constitution of FL3B. 5;6;8-11 The updated WHO classification of 2008, however, explicitly states that the presence of a diffuse component in FL3 warrants a separate diagnosis of diffuse large B cell lymphoma. Therefore, the vast majority of FL3B described in the literature would nowadays fall into this category. The fact that DLBCL associated with a FL3B component do frequently harbour translocations involving BCL6, one of the hallmark DOI: 10.3324/haematol.2011.042531
translocations of DLBCL, fits well with this concept. 5;6;10;11 The cytogenetic constitution of purely follicular FL3B, on the other hand, is largely unknown. In the present work, therefore, we set out to define the largest series available to date of FL3B with immunophenotypic and cytogenetic data, especially also paying attention to their sometimes difficult delineation from FL3A and related variants.
DESIGN AND METHODS

Lymphoma specimens
Twenty-three purely follicular lymphomas grade 3B (FL3B), referred to the Department of Figure 1D ). 15 Of those, four were classified as FL with large centocytes (mean proliferation index: 32%, range 20%-80%), and five as FL with high proliferation index (PI) (mean PI: 44%, range 30%-80%). In 15 (exclusively follicular) FL3, a straightforward and reproducible distinction between grades 3A and 3B was not possible. These cases were termed FL3 unclassified (FL3U; Figure 1C ). Only primary diagnostic lymphoid biopsies from DOI: 10.3324/haematol.2011.042531 5 untreated patients were included in the study. Table S1 gives an overview of all cases included in the study. The median age of patients was 60 years (range from 9 to 86 years).
Only one pediatric patient was identified in the present series with a diagnosis of FL grade 3 (9 years). Because we did not, for principal reasons, exclude pediatric patients from the series, we chose to keep this case in the study cohort. All cases were classified on the basis of routine hematoxylin and eosin (H&E), Giemsa and Perjodic acid Schiff (PAS) stainings and CD21 and/or CD23 immunostainings (see below).
Immunohistochemistry
Paraffin sections were immunostained for diagnostic purposes with antibodies directed against CD20 (clone L26, dilution 1:1000, DAKO, Glostrup, Denmark), CD5 (clone 4C7, 
RESULTS
Morphology and Clinical Data
The present series comprised 100 cases including 25 FL1/2, nine FL/LCC, 12 FL3A, 23 turned out that the classification of cases as FL3A was straightforward, if centroblasts and centrocytes differed markedly in size, and as FL3B, if the (large) centroblasts showed a homogeneous cytology ( Fig. 1A and B) . FL3U, however, in most cases, were difficult to classify, obviously owing to the smaller size of the blasts and to the presence of a smaller cell population that showed intermediate features not allowing for their unequivocal characterization as "small blasts" or "large centrocytes", as is shown in Figure 1C . We chose, however, not to build a consensus diagnosis, but to create a category of FL3, unclassified (FL3U) reflecting the obvious diagnostic uncertainty in some cases. Because of the retrospective nature of the study, no data on initial presentation or follow-up could be obtained. Data on age and sex of the patients are given in supplemental table S1. No significant differences were noted between FL subgroups.
Genetic Features
All cases were hybridized with break-apart probes flanking the breakpoints in the BCL2, BCL6 and MYC genes. In addition, we investigated 28 cases with a newly generated IRF4 break-apart probe. 18 BCL2 breaks were the predominant genetic feature in FL1/2 (22/25, 88%), FL/LCC (7/9, 78%) and FL3A (7/12, 58%), and were also observed in a significant proportion of FL3U (6/15, 40%). They were only infrequently detected, however, in FL3B Figure 2A ). In contrast, rearrangements of the BCL6 gene locus were most frequently observed in DLBCL/FL3B (8/16, 50%), and were also detected in small numbers in FL/LCC (2/9, 22%), FL3B (4/23, 17%), FL3A (2/12, 17%) and FL3U (2/15, 13%). No BCL6 breaks were observed within the group of FL1/2. Thus, the highest number of BCL6 breaks was encountered in DLBCL/FL3B (8/16, 50%), differing significantly from FL3B (p<0.05).
There was no significant difference between FL/LCC, FL3A and FL3B with respect to their overall low BCL6 rearrangement status (Table 1, Figure 2B ). Signal constellations indicative (Table S1 ).
Immunophenotypic features
By immunohistochemistry, FL1/2 turned out as a homogeneous entity, with all cases being positive for CD10 and all but one expressing BCL2 (24/25, 96%). All FL1/2 were negative for IRF4/MUM1 (Table 1 , Figures 3A and B) . A comparable staining pattern was evident for FL/LCC (CD10: 7/9, 78%; BCL2: 7/9, 78%; IRF4/MUM1: 0/9) and FL3A (CD10: 10/12, 83%; IRF4/MUM1: 0/5). FL3A, however, were BCL2 positive in only 50% (6/12) ( 1, Figure 3A ). BCL2 expression was significantly higher in FL1/2 when compared with FL3B
(9/20, 45%, p<0.001) ( , and these cases would nowadays be diagnosed as a diffuse large B cell lymphoma with an associated follicular FL3B component (DLBCL/FL3B). 1 The case set of the present work, therefore, is unique in that it represents the largest number of purely follicular FL3B reported on to date with available genetic and immunophenotypic data (n=23). In addition, we compare our molecular cytogenetic and immunohistochemical data on this exceedingly rare FL subset with another less well studied group of FL, tumours being predominantly composed of large centrocytes and/or displaying higher Ki67 indices (>30%, FL/LCC). 15 The main cytogenetic finding in our present case series, unrelated to our previously reported 6 that had been diagnosed as FL1/2 had been reclassified as FL3B during the course of disease, and four of these 6 were t(14;18) positive. In this publication, the reason for reclassification was not specified, and especially, it was not stated whether they had been reclassified because of transformation. Therefore, this either reflects a diagnostic inconsistency, or refers to a higher grade transformation of low-grade disease. For principal reasons, we had excluded transformed FL -that may well grow in follicular structures -in our series. Furthermore, in contrast to these series, a category of FL3U has been created among our cases. It is not clear, why the problem of subclassifying some cases of FL3A has not been addressed in previous reports of FL3. 13;20 Most probably, all the cases had been assigned to one of the two groups, because an FL3U group was not defined and therefore, an unequivocal classification had to be given.
Concerning the analysis of MYC rearrangements and the distribution of "double hit (DH)" or "triple hit (TH)" cases in our series, it is interesting to note that MYC translocations were detected -albeit in low frequencies -in all categories of FL (13%-22%) with the exception of FL1/2 and FL3A. This finding is well in agreement with the data from other studies, which (Table S1 ). Since a correlation of IRF4/MUM1
protein expression and translocation of the IRF4 gene has recently been demonstrated in pediatric lymphomas 18 , we also investigated the constitution of the IRF4 gene locus in FL subtypes with or without IRF4/MUM1 expression. However, none of the cases analyzed harboured a translocation involving IRF4. Since the median age of the patients analyzed for IRF4 translocations in our sample was 60 years (range 41y to 80y, data not shown), this is likely due to the fact that IRF4 translocations are mainly occurring in pediatric or young adult patients (15% versus 2% IRF4 translocations in adult FL patients 18 ). Only one pediatric patient (age: 9 years) was included in this study. Consistent with recent findings, this FL3U tumour sample (ID31 , Table S1 ) did not harbour a translocation of BCL2 and showed no BCL2 protein expression 4 , while it was characterized by a CD10 therefore, might be due to follicular colonization rather than true neo-formation of follicles.
FL3B, however, form an at present intermediate group of cases with only low levels of BCL2
and BCL6 rearrangements and by virtue of this, can be distinguished both from the groups of FL1-3A and from DLBCL. Clinical data on this still enigmatic tumour entity remain scarce and are retrospective in nature. They suggest, however, that the subclassification of FL3A and FL3B is not of clinical relevance, and that, in keeping with this finding, FL3B cannot be cured with at least conventional anthracycline-based chemotherapy protocols, again setting it apart from DLBCL. 13;20 In neither series, however, differences in immunophenotypes or the genetic constitution, as has been documented in our cases, had been taken into account. On the other hand, one study suggested that it is not the distinction of FL3A or FL3B that is crucial in assessing prognosis, but the question whether a diffuse component is present or not. 
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